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Electronic monitors are considered to be the gold standard for objectively quantifying adherence (1) . Most studies using electronic recording devices have reported adherence as the mean adherence or, the Mean Daily Dose, over the study period (2) (3) (4). However, this method does not reflect variations in the way that patients use their treatments. For example, the mean adherence is the same whether an individual took the medication according to the prescribed schedule or took all the doses in the first half of a dosing period, leaving none in the second half. Inhaler technique needs to be included in the assessment of adherence because an individual may take their inhaler according to the dosing schedule but with incorrect technique, resulting in no medication being delivered. In this case the average use over time is meaningless unless data on the technique of use is also incorporated into the calculation of the adherence. Most electronic recording devices usually do not assess if the inhaler was taken correctly (5) (6) (7) (8) (9) (10) (11) (12) . Hence, there is a need to develop a method to quantify adherence that accounts for variations in dosing schedules as well as inhaler user technique.
We developed a device, INhaler Compliance Assessment (INCA   TM   ) , which makes a digital file each time the inhaler is used (13) . Analysis of this information means that the time of use, the interval between doses and the proficiency of inhaler use can be assessed (13) . Technique errors identified by this method include failing to prime the inhaler, dispersing the medication by exhalation into the inhaler after priming and other errors such as dose dumping (14, 15) . In addition, the acoustic features of inhalation are highly reflective of objectively measured peak inspiratory flow, meaning that the device can estimate the peak inspiratory flow at each inhalation (16) , (17) .
The aim of this study was to test the hypothesis that by including the time of use, the interval between doses and accounting for inhaler technique, we could quantify adherence as an Area Under the Curve (AUC) and, furthermore, determine whether adherence calculated using AUC was more reflective of patient outcomes than current methods of assessing adherence. Some of the results of this study have been previously reported in the form of an abstract (18) .
Methods

Study Design
Patients for this study were prospectively recruited from five specialty asthma clinics in Ireland from January 2011 to December 2015. Participants included in this analysis include all asthma patients studied to date, both those who participated in the pilot preliminary study (n=32) and also from the single blind prospective multicentre randomised controlled clinical trial (n=207) which followed. The full protocol of the study has already been published (19) . All patients from both groups of the randomised control trial were combined to provide at least 6000 audio files for analysis (50% of prescribed inhalations over the month for 200 patients).
On enrolment the patients were shown how to use the inhaler and errors were corrected using a 10 point checklist inhaler proficiency score (20) (21) (22) . Over the following months (4, 8 and 12 weeks) the patients returned to the clinic, where inhaler technique was checked and improved if necessary, and adherence encouraged.
The primary endpoint of this manuscript was to describe inhaler adherence using a new method of calculating adherence and its relationship with clinical outcomes in asthma, such as quality of life, disease control and lung physiology.
Participants
Inclusion criteria were patients aged ≥18 already prescribed therapy equivalent to step 3 or higher on the Asthma Management Guidelines (23, 24) who, in addition, had at least one exacerbation treated with systemic glucocorticoids in the prior year. The dose of inhaled corticosteroid and long acting beta-agonist (LABA) was not changed during the study. Exclusion criteria included an unwillingness to participate in a clinical study or prior hypersensitivity to salmeterol/fluticasone. Asthma diagnosis was made using a clinician diagnosis supported by one or more of the following: obstructive spirometry with at least 12% reversibility, a positive bronchial provocation challenge or variability in the diurnal peak expiratory flow (PEF) of more than 15%. All patients provided written informed consent. The study was approved by local hospitals ethics committees and registered on Clinicaltrials.gov, NCT01529697.
Electronic Adherence Monitor
We have previously reported the development and validation of the INCA TM audio recording device in 60 patients with a total of 1200 audio recordings (13) . The device contains a microphone, internal clock, battery and memory card with plastic housing. It is attached to an inhaler and records the audio associated with an individual using their inhaler, see Figure 1 . In previous studies we have shown that inhaler errors such as low inspiratory flow and exhalation into the inhaler are easily identified. We have also shown that acoustic features of inhalation are directly proportional to peak inspiratory flow (14, 16, 17 
Extraction of Features of Inhaler Use and Calculating Adherence
Audio raters assessed each acoustic recording for evidence of critical errors, as previously described (13) (14) (15) . Critical errors in inhaler use, such as low inspiratory flow were classified as no dose. While non-critical errors, such as vertical position of the inhaler, were classified as a complete dose.
The interval between doses was calculated based on drug half-life and the measurement of doses taken was related to this drug interval (for this study, the pharmacokinetic profile and drug half-life of salmeterol was used). In the case of a dose taken within one half-life of the drug, after the previous dose, this was counted as one dose. Where the interval between doses was greater than one half-life and less than two half-lives, this was considered as 0. 
Analysis of Peak Expiratory Flow (PEF)
A similar method to that described above was used to analyse PEF data. Expected PEF was calculated based on age, sex and height.
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PEF variability (25) was calculated as the difference between AM and PM PEF AUC.
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Outcome Measures
At the end of each month the INCA TM device was collected from the participant. Audio data was downloaded from each device to provide information on inhaler use for the previous month. Additional information recorded at each visit included the Asthma Quality of Life Questionnaire (AQLQ), Asthma Control Test (ACT), the patient's self-reported reliever medication use, PEF and any recent exacerbations. Change in AQLQ (26, 27) was divided into those who did (improvers) and did not (non-improvers) have an improvement of 0.5 points (the minimal clinically important difference in AQLQ). Change in PEF was also categorised into improvers and non-improvers based on a 10% cut off (23, 24) .
Statistical Analysis
Descriptive statistics were used to present basic patient details for those included in this 
Results
Participants
The clinical characteristics of the 239 participants included in this analysis can be seen in Table   1 . The patient cohort was primarily female (62%) with a mean (SD) age of 49 (16.1) years. A large proportion of patients in this cohort were poorly controlled with a mean AQLQ of 3.9, ACT of 12.2 and 145 (61%) patients used a short acting beta-agonist on a daily basis.
Baseline Adherence to Inhaled Therapy
In the first month there were 11 (<6%) device failures, 5 (<3%) devices were lost and a further 6 (<3%) patients had missing dose counter information. The total number of audio files, for the first month, with evidence of drug priming was 7973, compared to a total of 8169 doses on the dose counter (correlation coefficient = 0.981 Using an 80% cut off to indicate good adherence, 67 (30%) patients had good ‫)ܥܣ(݂‬ over the first month of inhaler use. This was much lower than that calculated using other adherence measures, see Table 3 . As a result the Average Adherence, using the dose counter, had 37.1% sensitivity and 93.0% specificity, with a 90.2% positive and 46.2% negative predictive value to Actual Adherence, ‫,)ܥܣ(݂‬ see Table 3 .
Associations between Adherence Measures and Clinical Outcomes
Quality of life. Patient reported AQLQ change from the start of the monitoring period to the end of the study was analysed. for non-improvers), see Figure 4 .
For the purpose of this analysis, an AQLQ ≥5 was considered to be indicative of a good quality of life score (26, 27) . At month three, both good quality of life score (AQLQ ≥5) and good adherence (≥80%) were seen in 17% of patients when adherence was calculated by the ‫)ܥܣ(݂‬ method compared to 36% when adherence was calculated using the dose counter. In contrast, among those with an AQLQ <5, 35% had an ‫)ܥܣ(݂‬ <80% and only 16% had an average dose counter adherence <80% (p<0.01, χ 2 test). The sensitivity and specificity of the various measures of adherence in identifying patients with an improvement in AQLQ is shown in Table   4 . Table 4 . 
Limitations
There are several limitations in this study. Firstly, the patients studied were already prescribed inhaled salmeterol/fluticasone for some time. Hence, it is not too surprising that there were relatively small changes in lung function and quality of life. Furthermore, the duration of follow up was relatively short and possibly not of sufficient duration to see more significant correlations with clinical parameters (33) . Nonetheless, the novel measurement of adherence that we have described demonstrated significant associations with several measures of asthma over the timeframe, demonstrating its appropriateness. Future experimental tests of the approach described here will involve testing in larger populations and for longer periods of time.
We have previously described the close relationship of acoustically assessed PIF with objectively measured PIF (14, 16, 17) . We have also described the significant effect of both low PIF and that of exhalation into the inhaler on drug delivery (14, 16, 17, 34) . 
Conclusions
We have developed a method of calculating inhaler adherence modelled on the concepts of drug pharmacokinetics that incorporates both the time and the technique of use of an inhaler.
This method not only identifies which component of adherence is deficient but is also more reflective of the clinical changes expected from a medication than current methods used to assess adherence. Non-improvers similarly showed no relationship between adherence and change in AQLQ. In (c) the relationship between the changes in AQLQ and Attempted Adherence is shown. Nonimprovers had a higher adherence rate for a bigger drop in AQLQ, similar to Mean Daily Dose;
however improvers had a better adherence rate as the improvement in AQLQ increased. In (d) Column A is an example of a patient with perfect adherence over a 30 day period. Attempted Adherence, f(AT) is perfect, 60 doses taken over 30 days. There were no missed doses, no technique errors, and the interval between doses is within one half-life, the Actual Adherence rate, f(AC), is 1.00 (100%). Column B is an example where the medication was taken only once daily for 30 days. The Attempted Adherence, f(AT) is half that of column A and there were 30 missed doses over 30 days. In this example there were no technique errors. Due to missing doses every day the interval between doses was also poor and f(AC) is 0.50 (50%). Column C is an example of a patient who takes the medication (with no technique errors) every day, twice a day, but with erratic timing. There was perfect Attempted Adherence, with no missed doses and no technique errors. Due to the erratic time of use, some doses which have an interval beyond the half-life of the drug, f(i), the f(AC) is reduced to 0.92 (92%). Finally, column D is an example of a patient who takes the medication only once daily and makes a technique error for the first 15 days of the 30 days. Therefore, the, f(AT) is half that of expected (50%) due to missing 30 doses. There FIGURE 3: Graphical representation of adherence calculated in a number of ways. The data used for this graph is the first month's inhaler use by a cohort of 217 (of 239) asthma patients enrolled in a prospective adherence intervention clinical study who were asked to use a dry powder inhaler twice daily. The Actual Adherence rate, f(AC), is significantly different than the adherence calculated using the current methods, e.g. Average Adherence from the dose counter and the Mean Daily Dose, and the attempted rate, f(AT) (the electronic time of use measure), p<0.001. Figure 3  705x540mm (72 x 72 DPI) FIGURE 4: Asthma Quality of Life (AQLQ) value was recorded on a monthly basis, the minimal clinically important improvement in AQLQ is a 0.5 increase. Patients were divided into those who had a change in AQLQ ≥0.5 over three months (improvers) and those with a change <0.5 (non-improvers). In (a) the relationship between the changes in AQLQ and Average Adherence calculated from the DiskusTM dose counter is shown. Using this method of calculation of adherence, paradoxically, non-improvers had a higher level of adherence than those who improved. In (b) the relationship between the changes in AQLQ and Mean Daily Dose is shown. Non-improvers similarly showed no relationship between adherence and change in AQLQ. In (c) the relationship between the changes in AQLQ and Attempted Adherence is shown. Nonimprovers had a higher adherence rate for a bigger drop in AQLQ, similar to Mean Daily Dose; however improvers had a better adherence rate as the improvement in AQLQ increased. In (d) the relationship between the changes in AQLQ and Actual Adherence is shown. Non-improvers had low adherence rates, which increased as the fall in AQLQ decreased and improvers had higher adherence rates, which improved as the change in AQLQ increased. There was a significant difference comparing Average Adherence (dose counter) with Actual Adherence and Average Adherence with Attempted Adherence, p<0.01 and p<0.03 respectively. 
